KumarSK, CallanderNS, AdekolaK, et al.NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2023. Accessed November 9, 2022. To view the most recent version, visithttps://www.nccn.org
KumarSK, CallanderNS, AdekolaK, NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2023. Accessed November 9, 2022. To view the most recent version, visithttps://www.nccn.org)| false
DiamondB, KordeN, LesokhinAM, et al.Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Hematol2021;8:e422–432.
DiamondB, KordeN, LesokhinAM, Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Hematol 2021;8:e422–432.)| false
San-MiguelJ, Avet-LoiseauH, PaivaB, et al.Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of darat5umumab in MAIA and ALCYONE. Blood2022;139:492–501.
San-MiguelJ, Avet-LoiseauH, PaivaB, Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of darat5umumab in MAIA and ALCYONE. Blood 2022;139:492–501.34269818)| false
